Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis

OBJECTIVE: Analyse the integrated safety profile of evobrutinib, a Bruton’s tyrosine kinase inhibitor (BTKi), using pooled data from multiple sclerosis (MS), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) trials. METHODS: Phase II, randomised, double-blind, placebo-controlled trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Montalban, Xavier, Wallace, Daniel, Genovese, Mark C, Tomic, Davorka, Parsons-Rich, Dana, Le Bolay, Claire, Kao, Amy H, Guehring, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Multiple Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763187/
https://www.ncbi.nlm.nih.gov/pubmed/36418156
http://dx.doi.org/10.1136/jnnp-2022-328799

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9763187/
https://www.ncbi.nlm.nih.gov/pubmed/36418156
http://dx.doi.org/10.1136/jnnp-2022-328799

Ejemplares similares